In previous research, when CTX was combined with Interferon type I (IFN-I) in vivo, it delayed tumor development and prevented 60% of mice bearing two types of T-cell lymphoma, whereas CTX or IFN alone did not prevent tumor-bearing mice [51]. Here, IFNA1 is linked to T-cell non-Hodgkin lymphoma.